A. M. Trentacosti

Physicians' use of and preferences for FDA-approved prescribing information.

Helen W. Sullivan, C. Squire, K. Aikin, 2021, Research in social & administrative pharmacy : RSAP.

Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations

M. Rowbotham, Z. Bhagwagar, J. Farrar, 2012, PAIN.

PCN122 DEVELOPMENT OF THE PATIENT-REPORTED VERSION OF THE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (PRO-CTCAE)

A. Abernethy, L. Minasian, E. Basch, 2010 .

The Use of Patient‐Reported Outcome Measures in the Evaluation of Medical Products for Regulatory Approval

L. Burke, D. Kennedy, A. M. Trentacosti, 2008, Clinical pharmacology and therapeutics.

Evolution of Clinical Trials for Irritable Bowel Syndrome: Issues in End Points and Study Design

L. Burke, D. Kennedy, A. M. Trentacosti, 2010, The American Journal of Gastroenterology.

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutated -Metastatic Castrate Resistant Prostate Cancer.

M. Anscher, K. Goldberg, R. Pazdur, 2020, The oncologist.

Pain palliation measurement in cancer clinical trials: The US Food and Drug Administration perspective

E. Basch, L. Burke, R. Pazdur, 2014, Cancer.

Stakeholder perspectives on implementing the National Cancer Institute’s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

A. Abernethy, L. Minasian, E. Basch, 2011, Translational behavioral medicine.